Drug intelligence / Profile preview

PEP07

Development stage: Phase 1
Lead developer: PharmaEngine
Modality: Small Molecules
Administration: Oral

Overview

PEP07 is an orally bioavailable, brain-penetrant small molecule inhibitor of checkpoint kinase 1 (Chk1), developed for its potential antineoplastic and chemosensitization activities. By selectively binding to Chk1, PEP07 inhibits its activity and disrupts the repair of damaged DNA in cancer cells, thereby enhancing the cytotoxic effects of DNA-damaging agents. It is being investigated primarily for relapsed/refractory acute myeloid leukemia (AML), mantle cell lymphoma (MCL), metastatic solid tumors, and non-small cell lung cancer. The drug is currently in Phase 1 clinical trials[1][2][3][4][5][7].

Other names: chk1 inhibitor pep07chk-1 inhibitor pep07chk 1 inhibitor pep07

Targets

CHEK1 (Checkpoint kinase 1)

Beyond the preview

Go deeper on PEP07.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PEP07.

Explore the full profile